David B. Solit
YOU?
Author Swipe
View article: Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer Open
HER2, encoded by the ERBB2 gene, is a receptor tyrosine kinase frequently activated in human cancers via gene amplification, mutation, and/or protein overexpression. In an analysis of 42,415 prospectively analyzed solid tumors, we show tha…
View article: Hypoxia and tumor associated macrophages shape response to immune and angiogenesis-targeted therapies in metastatic clear cell renal cell carcinoma 3738
Hypoxia and tumor associated macrophages shape response to immune and angiogenesis-targeted therapies in metastatic clear cell renal cell carcinoma 3738 Open
Description Clear cell renal cell carcinoma (ccRCC) is driven by biallelic loss of VHL, leading to pseudohypoxia & elevated angiogenesis. Thus, anti-angiogenesis tyrosine kinase inhibitors (TKI) became the effective standard of care for me…
View article: Influence of sex on immunosurveillance and metastatic tropism in novel mouse models of clear cell renal cell carcinoma 4060
Influence of sex on immunosurveillance and metastatic tropism in novel mouse models of clear cell renal cell carcinoma 4060 Open
Description Sex bias in renal cell carcinoma (RCC) is marked by males having twice the incidence and mortality of females, along with larger, higher-grade tumors and greater metastatic burden. Using two syngeneic RCC mouse models, one immu…
View article: 14Influence of sex on immunosurveillance and metastatic tropism in novel mouse models of clear cell renal cell carcinoma
14Influence of sex on immunosurveillance and metastatic tropism in novel mouse models of clear cell renal cell carcinoma Open
Background Sex bias in renal cell carcinoma (RCC) is marked by males having twice the incidence and mortality rates of females, along with larger, higher-grade tumors and greater metastatic burden. Several hormonal, genetic, and behavioral…
View article: 34Hypoxia and immune suppression shapes therapeutic outcomes and metastases in clear cell renal cell carcinoma
34Hypoxia and immune suppression shapes therapeutic outcomes and metastases in clear cell renal cell carcinoma Open
Background Vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (VEGFR-TKIs) and aPD1 combinations are effective in multiple solid tumors, particularly in clear cell renal cell carcinoma (ccRCC), due to its char…
View article: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer Open
With the approval of the antibody-drug conjugate enfortumab vedotin (EV), NECTIN4 has emerged as a bona fide therapeutic target in urothelial carcinoma (UC). Here, we report the development of a NECTIN4-directed chimeric antigen receptor (…
View article: Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer Open
PURPOSE An estimated 25% of patients with biliary tract cancer (BTC) do not undergo genotyping, representing a missed opportunity for therapeutic targeting. METHODS Cell-free DNA (cfDNA) and matched tumor sample from patients with BTC were…
View article: Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkers
Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkers Open
Accurate cancer subtyping with accompanying molecular characterization is critical for precision oncology. While machine learning approaches have been applied to both digital pathology and cancer genomics, previous work has been limited in…
View article: Data from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Data from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Purpose:To address financial barriers that limit access to genomic profiling and precision medicine, philanthropy-supported clinical genomic testing was offered worldwide at no cost to patients with select rare cancers via the Make-an-IMPA…
View article: Supplementary Table 1 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Supplementary Table 1 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Supplementary Table 1. Table representing country of referral for patients enrolled on the Make An Impact program (n = 63).
View article: Supplementary Figure 1 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Supplementary Figure 1 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Supplementary Figure 1. Overview of the workflow involved from patient outreach, screening, enrollment, testing and return of results to local physician/patient.
View article: Supplementary Table 3 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Supplementary Table 3 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Supplementary Table 3. Clinical, demographic and molecular characteristics of pediatric CNS tumor patients enrolled on the Make an Impact program.
View article: Supplementary Figure 2 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Supplementary Figure 2 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Supplementary Figure 2. Overview of the analytical pipeline for interpretation of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA).
View article: Supplementary Table 2 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers
Supplementary Table 2 from Improving Global Access to Genomic Profiling in Rare Pediatric Cancers Open
Supplementary Table 2. Clinical, demographic and molecular characteristics of pediatric solid tumor patients enrolled on the Make an Impact program.
View article: Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Generation of acquired resistance PDX model
View article: Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
C106 resistant cells drug withdrawal and Patient #12 MSK-Impact data
View article: Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Oncoprint of baseline alterations in CRC patients who developed resistance to KRAS G12C and EGFR inhibitors
View article: Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Characterization of acquired resistance in vitro models
View article: Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
C106 cell lines single cell sequencing analysis
View article: Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Patients Longitudinal Cell Free DNA data
View article: Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
RW7213 cell lines sequencing analysis
View article: Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Patients Characteristics
View article: Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer Open
Patients Progression Cell Free DNA data
View article: Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance) Open
We looked at the link between tumor DNA present in blood and outcomes after chemotherapy for patients with advanced bladder cancer. Higher amounts of tumor DNA in blood and mutations in specific cancer genes were linked to worse survival. …
View article: RETRACTED: Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors
RETRACTED: Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors Open
21 March, 2025. This preprint was retracted at the authors' request due to a conflict with a conference embargo policy. Authors should verify embargo policies before posting to avoid post-publication removal.